[Comment] Tofacitinib in rheumatoid sarcopenia

Sarcopenia causing loss of muscle mass and strength is relatively common in rheumatoid arthritis, with previous small studies reporting the prevalence ranging from 4·5% to 44% of people with rheumatoid arthritis, depending on the definition of sarcopenia used.1–3 In rheumatoid arthritis, sarcopenia is mediated by inflammation-driven proteolysis, reduced physical activity due to musculoskeletal inflammation and pain, and the use of sarcopenic drugs such as glucocorticoids.3 Rheumatoid sarcopenia increases the risk of fall, fractures, disability, and hospitalisation.